CG Oncology CGON
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
CG Oncology (CGON) Business Model and Operations Summary
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
Key Insights
CG Oncology (CGON) Core Market Data and Business Metrics
Latest Closing Price
$22.05Market Cap
$1.68 BillionPrice-Earnings Ratio
-15.64Total Outstanding Shares
76.22 Million SharesTotal Employees
113Dividend
No dividendIPO Date
January 25, 2024SIC Description
Biological Products, (no Disgnostic Substances)Primary Exchange
NASDAQHeadquarters
400 Spectrum Center Drive, Irvine, CA, 92618
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities | $-78.71 Million |
| Net Cash Flow From Investing Activities | $-300.76 Million |
| Net Cash Flow From Operating Activities, Continuing | $-78.71 Million |
| Net Cash Flow | $248.80 Million |
| Net Cash Flow From Financing Activities, Continuing | $628.28 Million |
| Net Cash Flow, Continuing | $248.80 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Income/Loss From Continuing Operations After Tax | $-88.04 Million |
| Other Operating Expenses | $33.70 Million |
| Net Income/Loss Attributable To Parent | $-88.04 Million |
| Diluted Average Shares | $62.50 Million |
| Nonoperating Income/Loss | $26.63 Million |
| Income/Loss From Continuing Operations Before Tax | $-88.04 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Other Comprehensive Income/Loss | $0 |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss Attributable To Parent | $-88.04 Million |
| Comprehensive Income/Loss | $-88.04 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Fixed Assets | $272,000 |
| Equity Attributable To Noncontrolling Interest | $0 |
| Equity | $733.38 Million |
| Current Liabilities | $21.37 Million |
| Current Assets | $754.21 Million |
| Equity Attributable To Parent | $733.38 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||